Refine by
Preclinical Studies Suppliers Near Monaco
141 companies found
based inBerlin, GERMANY
iMouse GmbH, a Berlin-based company specializing in digital home cage monitoring solutions for preclinical research. Their flagship product, the iMouse system, aims to enhance objectivity, reduce human bias, and improve animal welfare in laboratory ...
iMouse GmbH offers a sophisticated AI-powered platform that is revolutionizing preclinical studies by providing digital biomarkers. This system processes video data of mice, converting their activities into ...
based inNorcross, GEORGIA (US) (USA)
Xstrahl is a prominent global provider specializing in the development and delivery of superficial radiation therapy devices and advanced preclinical radiation research systems. The company is actively engaged in connecting experts to further the ...
The SARRP FLASH system by Xstrahl exemplifies cutting-edge technology in preclinical radiation therapy. This system leverages the advanced FLASH-RT technique, which administers ultra-high dose rates of radiation, significantly surpassing ...
based inNEW YORK (USA)
Ace Therapeutics is a preclinical contract research provider. With a team of experienced researchers and top-tier facilities, Ace Therapeutics offers tailored solutions from basic research services to preclinical study services to accelerate the ...
based inUnion City, CALIFORNIA (USA)
Fibralign is an award-winning, commercial-stage, Stanford-spinout that designs, develops and produces novel therapeutic medical devices to address major unmet medical needs. Based in the San Francisco Bay Area, the company’s team has established GMP ...
Fibralign is developing a pipeline of compelling novel products which are based on its proprietary Nanoweave® scaffolding platform that can be tailored to address a wide range of high-value applications. Nanoweave technology provides the means ...
based inMelbourne, AUSTRALIA
Mesoblast is using its proprietary mesenchymal lineage cell technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care. ...
MPC-06-ID is a Phase 3 product candidate for the treatment of chronic low back pain caused by disc degeneration (CLBP). It is being developed for patients who have exhausted conservative treatment options, may have failed epidural steroid ...
based inSunrise, FLORIDA (USA)
U.S. Stem Cell, Inc. (OTC:USRM) is an emerging leader in the worldwide development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions. Based in Sunrise, Florida, the Company has developed a clinical ...
MyoCell SDF-1 has received approval from the FDA to begin human clinical trials and is intended to be an improvement to MyoCell. The myoblast cells to be injected are gene-modified prior to injection by an adenovirus vector so that they will release ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
based inEncinitas, CALIFORNIA (USA)
Neurodigitech (NDT) is dedicated to 1) Neurohistological and neuropathological services of the central nervous system (CNS), 2) Neural staining kits, 3) High-throughput digital microscopic imaging and stereology-based quantitative morphology, and 4) ...
In particular, NDT is dedicated to custom-designed neuropathological assessments for the neurodegenerative diseases, such as Alzheimer's, Parkinson's, ALS, and brain insults (strokes and brain tumors) and Human neural stem cell and small molecule ...
based inAtlanta, GEORGIA (US) (USA)
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a ...
This creates robust tumor-specific immunity that Metaclipse anticipates will destroy and/or suppress the growth of metastatic cancer cells. Our preclinical studies demonstrated that our vaccine immunotherapy acts ...
based inLa Tronche, FRANCE
INOVOTION is a Contract Research Laboratory implementing a unique approach to in vivo evaluation for anticancer drug discovery. Our cutting-edge proprietary technology provides early analysis of your compounds before the classical preclinical stage. ...
Pharmaceutical chemical and biology researchers need to develop new methods and models to improve the predictivity of preclinical discovery phases and increase the number of good molecules in clinic. INOVOTION’s unique in vivo technology ...
based inWroclaw, POLAND
Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based ...
Neuromyelitis optica (NMO) is an neurological autoimmune condition classified as a rare disease. Because of this classification, NMO lacks effective treatment options, since it is not of primary interest to the pharmaceutical industry. However, ...
based inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
Pre-clinical studies showed that LB-100 alone inhibits a spectrum of human cancers but when combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing ...
based inSouth Melbourne, AUSTRALIA
BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. Our business model is to generate income from partnerships including with other vaccine and infectious ...
A core technology advantage: Live Attenuated Influenza Virus (LAIV) vaccine. BioDiem’s lead asset is the Live Attenuated Influenza Virus (LAIV) vaccine technology. Our LAIV vaccine licensing business involves out-licensing of the ...
based inPearl River, NEW YORK (USA)
Auro Vaccines LLC is a clinical-stage vaccine development company pioneering a major evolutionary step in the design and development of preventive and therapeutic vaccines for infectious diseases. Our novel approach is based on a proprietary ...
Auro Vaccines has developed a VesiculoVax™-vectored vaccine to protect against the arthralgic disease caused by infection with Chikungunya ...
based inNoida, INDIA
Advancells is a research-oriented company, focussed on offering authentic, high-quality primary cells including stem cells for research studies, stem cell therapy, preclinical analysis, and even as in vitro tools for clinical research. We wish to be ...
Muscular dystrophy is a group of disorders, characterized by progressive degeneration of skeletal muscles and muscle weakness. There are nine different types of dystrophies and all of them are associated with the faulty gene dystrophin that creates ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
APVO436 is an optimized ADAPTIR bispecific antibody candidate designed to redirect T-cell cytotoxicity through the dual targeting of CD3, a T-cell co-receptor that promotes cytotoxicity, and CD123, a cell surface receptor highly expressed in several ...
based inGolden, COLORADO (USA)
At Vitro Biopharma, our goal is to become a leader in developing differentiated product candidates in a rapid and efficient manner for the immunology and inflammatory market, and ultimately, to address well-established multi-billion-dollar ...
based inMelbourne, AUSTRALIA
Starpharma Holdings Limited is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP drug delivery and ...
DEP® cabazitaxel is an enhanced version of leading prostate cancer drug cabazitaxel (Jevtana®). Cabazitaxel (Jevtana®) had global sales of €536M in 2020 despite having multiple US FDA “Black Box” warnings. ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
We are developing CYNK-101 as a combination treatment for multiple cancer indications. CYNK-101 is manufactured from a specific type of immune cell, NK cells, that we extract from postpartum placentas and then genetically engineer to increase cell ...
based inMorrisville, NORTH CAROLINA (USA)
Istari Oncology, Inc., is a clinical-stage biotechnology company developing innovative immunotherapies for the treatment of patients with solid tumors. Istari has built a passionate and experienced leadership team focused on clinical trial strategy ...
The tumor environment contains all the ingredients needed to mount an anticancer immune response—tumor antigens, antigen presenting cells (APCs, including tumor-associated macrophages [TAMs] and dendritic cells), and T cells—but ...